Showing results (121-130 of 139) with videos related to
Sort By:
Pageof 14
Journal for Immunotherapy of Cancer|September 14, 2021
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinomaTim F Greten, Ghassan K Abou-Alfa, Ann-Lii Cheng, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2021
Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II StudyRobin Kate Kelley, Bruno Sangro, William Harris, et al.Age and Ageing|November 9, 2025
Development and validation of ACTTOP: a prediction model for severe anticancer treatment toxicities in older patients with solid malignancyWing Lok Chan, Holly Li-Yu Hou, Horace Chuek-Wai Choi, et al.Journal of Hepatology|August 1, 2024
Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinomaGeorge Lau, Ghassan K Abou-Alfa, Ann-Lii Cheng, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 29, 2018
Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with <i>RAS</i>-Mutated Hepatocellular CarcinomaHo Yeong Lim, Philippe Merle, Karl Heinz Weiss, et al.The Lancet. Oncology|December 16, 2021
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trialThomas Yau, Joong-Won Park, Richard S Finn, et al.Clinical Colorectal Cancer|October 27, 2016
Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC StudyAnn-Lii Cheng, Gerardo Cornelio, Lin Shen, et al.Breast Cancer Research and Treatment|September 23, 2021
Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimensMing Shen Dai, Yin Hsun Feng, Shang Wen Chen, et al.Lancet (London, England)|May 11, 2025
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trialThomas Yau, Peter R Galle, Thomas Decaens, et al.NEJM Evidence|February 6, 2024
Tremelimumab plus Durvalumab in Unresectable Hepatocellular CarcinomaGhassan K Abou-Alfa, George Lau, Masatoshi Kudo, et al.Pageof 14